Patients with fibromyalgia respond to tailored psychotherapy.
It is best to intervene before the physical and psychological impairments have hardened. Also, combining the tailored psychotherapy with an exercise training program seems to be important, mental health researchers said at the annual European Congress of Rheumatology.
Saskia van Koulil, Ph.D., summarized her recent comprehensive review of the published literature on nonpharmacologic therapies for fibromyalgia (Ann. Rheum. Dis. 2007;66:571-81) as showing modest and inconsistent benefits. In many studies, 30% or fewer of treated patients had at least a 50% improvement in symptoms and functioning, and the benefits typically faded over 6 months or more of follow-up.
But this poor showing is probably attributable to a past tendency to take a one-size-fits-all approach to psychotherapy for what is in reality a quite heterogeneous syndrome, said Dr. van Koulil of Radboud University, Nijmegen (the Netherlands).
She and her coworkers have developed a validated brief self-report screening instrument (Int. J. Behav. Med. 2008;15:211-20) to help differentiate the two major cognitive and behavioral patterns fibromyalgia patients exhibit: pain-avoidance behavior, which is an extension of the well-established psychological fear-avoidance model, and a pain-persistence pattern, in which patients ignore their pain and persist in painful activities to their detriment. The two patterns are equally common.
Fibromyalgia patients with a pain-avoidance pattern are more likely to benefit from operant-behavioral therapy focused on changing observable pain behaviors, while those with a predominantly pain-persistence pattern tend to fare better with cognitive-behavioral therapy addressing maladaptive thoughts. For patients who have elements of both patterns, either form of therapy appears to be appropriate, according to Dr. van Koulil.
She presented a randomized trial in which 216 fibromyalgia patients were as signed either to a multimodal inter vention--including tailored psychotherapy--or to a usual-care control group. All had high levels of psychological distress as an inclusion criterion, in light of evidence that nonpharmacologic therapies are most effective in such patients.
The intervention consisted of small, 3-hour group sessions twice weekly for 8 weeks. Half of each session was devoted to tailored group psychotherapy, the other half to exercise training, which included pool exercise and aerobics, and relaxation therapy. The patient's significant other attended three sessions so therapists could address social reinforcement issues.
At the end of the intervention, patients rated its usefulness as 8.2 out of a possible 10. They also showed highly clinically relevant 80%-90% reductions on measures of pain, fatigue, functional disability, and anxiety.
More important, at 6-month follow-up, 57% of the multimodal intervention group maintained a clinically significant improvement as defined by at least a 0.5-standard deviation gain over baseline on physical functioning measures, compared with 29% of controls. And 49% of the intervention arm showed a similar improvement in psychological functioning, compared with 28% of controls.
Based on these favorable results, the tailored nonpharmacologic intervention will be implemented nationally at other Dutch university medical centers, Dr. van Koulil added.
Kati Thieme, Ph.D., reported on 125 fibromyalgia patients randomized to cognitive-behavioral therapy, operant behavioral therapy, or a control group. Patients were followed for 12 months, at which point she and her colleagues looked retroactively at various pretreatment patient characteristics to see which ones separated subsequent responders from non-responders.
The psychotherapy consisted of 15 once-weekly 2-hour sessions conducted in small groups codirected by a psychologist and a rheumatologist. The control group met on the same schedule for therapist-guided general discussions of the medical and emotional problems of fibromyalgia, with no therapist recommendations. Spouses attended four sessions. Patients were encouraged to increase their level of physical activity
At 1 year follow-up, clinically meaningful improvements in pain intensity measures were documented in 54% of patients in the operant-behavioral therapy group, a statistically similar 45% of the cognitive-behavioral therapy group, and 5% of controls. In the operant-behavioral therapy group, 58% had significant reductions in physical impairment, as did 38% in the cognitive-behavioral therapy group and 7.5% of controls, according to Dr. Thieme of the University of Heidelberg (Germany).
In the cognitive-behavioral group, re sponders had higher baseline levels of affective distress and physical impairment than did nonresponders. Responders also displayed less-pronounced pain behaviors at baseline, lower coping ability, and less enabling behavior on the part of spouses.
Responders to operant-behavioral therapy had greater baseline physical impairment than did nonresponders. Responders also had more mental catastrophizing, more pain behaviors, markedly more physician visits, and more solicitous spouse behaviors than did nonresponders to cognitive-behavioral therapy.
Clinically significant deterioration in pain behaviors and physical impairment were reported by 48% of patients in the control group, which implies that social discussion of fibromyalgia-related problems in the absence of therapeutic intervention may be counterproductive, Dr. Thieme cautioned.
A prospective outcome study is warranted to confirm the hypothesis that tailoring therapy according to the patient characteristics identified in this trial actually results in better outcomes, she continued.
"I think the central message is to find out which patients can profit from non pharmacologic treatment. Then we can evaluate which patients can profit from which pharmacologic treatments and combine the nonpharmacologic therapy with the pharmacologic. I think this is the new way," Dr. Thieme said.
Dr. Thieme's study was funded by the German Research Council. Dr. van Koulil's was supported by the Dutch Arthritis Association.
BY BRUCE JANCIN
|Printer friendly Cite/link Email Feedback|
|Publication:||Internal Medicine News|
|Date:||Dec 1, 2008|
|Previous Article:||New antidepressant effective in fibromyalgia.|
|Next Article:||Smoking cessation reduces disease burden in RA.|